权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

NCI ETCTN Pittsburgh Cancer Consortium (PCC)

NCI ETCTN 匹兹堡癌症联盟 (PCC)

基本信息

批准号：
10784844
负责人：
Jan Hendrik Beumer
金额：
$ 61.17万
依托单位：
UNIVERSITY OF PITTSBURGH AT PITTSBURGH
依托单位国家：
美国
项目类别：
财政年份：
2014
资助国家：
美国
起止时间：
2014-03-25 至 2026-02-28
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10784844
关键词：
Acceleration Adult Albert Einstein Cancer Center Antineoplastic Agents Biological Markers Cancer Center Cancer Patient Cancer Therapy Evaluation Program Catchment Area Characteristics Clinical Clinical Drug Development Clinical Trials Clinical Trials Network Comprehensive Cancer Center Conduct Clinical Trials Development Drug Kinetics Early Therapeutic-Clinical Trials Network Enrollment Florida Goals Health Infrastructure Institution Investigation Investigational Therapies Lead Leadership Malignant Neoplasms Mission Molecular National Cancer Institute Patients Pennsylvania Pharmaceutical Preparations Phase Phase II Clinical Trials Process Productivity Program Development Regimen Series Therapeutic Agents Toxic effect Universities University of Pittsburgh Cancer Institute Work anticancer research appropriate dose cancer care cancer therapy clinical development drug development early phase clinical trial experience interest member novel novel therapeutics phase I trial phase II trial programs response tumor

项目摘要

Abstract For more than 40 years, the National Cancer Institute (NCI) has supported an infrastructure program to conduct clinical trials across the US. To enhance, facilitate, and expedite the process of early-phase drug development, the NCI implemented a comprehensive plan transforming the NCI-sponsored early-phase clinical trials program from a series of separate institutions and efforts to a new, consolidated, integrated program, referred to as the NCI Experimental Therapeutics Clinical Trials Network (ETCTN). The UPMC Hillman Cancer Center (formerly the University of Pittsburgh Cancer Institute, hereafter referred to as ‘HCC’) has been an NCI-designated comprehensive cancer center since 1990, and has been involved in the NCI Early Drug Development Program since 1999. Our group was one of 12 academic centers to be selected as an ETCTN Lead Academic Organization (LAO) for the phase 1 component, and subsequently selected as one of 10 academic centers to integrate phase 2 clinical trial efforts, with responsibility for developing, leading, and accruing to ETCTN clinical trials for adult cancer patients. We now propose to be a member of the NCI ETCTN as the Pittsburgh Cancer Consortium (PCC) Lead Academic Organization in a consortium with the University of Florida Health Cancer Center and the Albert Einstein Cancer Center. The goal of the PCC is to create a unified, integrated clinical trials network that will allow for more seamless advancement and progress of novel experimental agents and/or combinations through early stages of drug development. The eventual goal of our program is to greatly facilitate and accelerate the delivery of new cancer therapies to the citizens of Pennsylvania, North-Central Florida, Bronx, NY, and their respective catchment areas.

摘要